Safety Evaluated Across 3 Head-to-Head Phase 3 Studies Including More Than 5,600 Patients
Xgeva® is not cleared by the kidneys and does not require dose adjustments, regardless of renal function1-6
| Renal considerations | |||
|---|---|---|---|
| zoledronic acid7 | Xgeva®1-6 | ||
| Cleared by kidneys? | Yes | No | |
| Dose adjustment required for baseline renal impairment? | Yes | No | |
| Dose withholding required for declining renal function during therapy? | Yes | No | |
Based on clinical trials using a lower dose of denosumab, patients with a creatinine clearance less than 30 mL/min or receiving dialysis are at greater risk of severe hypocalcemia compared to patients with normal renal function.8
Fewer acute phase reaction events were reported in the XGEVA® arm9*
| zoledronic acid | Xgeva® | |
| All events | 20.2% | 8.7% |
| Pyrexia | 7.2% | 0.6% |
| Fatigue | 2.5% | 1.7% |
| Bone pain | 2.4% | 1.1% |
| Arthralgia | 2.2% | 1.1% |
| Chills | 2.0% | 0.1% |
- *Acute phase reaction events occurred within the first 3 days of treatment, and the most common were pyrexia, fatigue, bone pain, arthralgia, and chills.9
Supplement with calcium and vitamin D as necessary to prevent or treat hypocalcemia8,10-12
- Help XGEVA® (denosumab) patients by emphasizing the importance of supplementing treatment with calcium ≥ 500 mg and vitamin D ≥ 400 IU daily as necessary to prevent or treat hypocalcemia8,10-12
See Xgeva® dosing & administration
